Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes.
Carmelina Cristina ZirafaGaetano RomanoElisa SicoloElena BagalàBeatrice ManfrediniGreta AlìAndrea CastaldiRiccardo MorgantiFederico DaviniGabriella FontaniniFranca MelfiPublished in: Current oncology (Toronto, Ont.) (2023)
Locally advanced non-small cell lung cancer (NSCLC) consists of a heterogeneous group, with different pulmonary extension and lymph nodal involvement. Robotic surgery can play a key role in these tumours thanks to its technological features, although open surgery is still considered the gold-standard approach. Our study aims to evaluate the surgical and oncological outcomes of locally advanced NSCLC patients who underwent robotic surgery in a high-volume centre. Data from consecutive patients with locally advanced NSCLC who underwent robotic lobectomy were retrospectively analysed and compared with patients treated with open surgery. Clinical characteristics and surgical and oncological information were evaluated. From 2010 to 2020, 131 patients underwent anatomical lung resection for locally advanced NSCLC. A total of 61 patients were treated with robotic surgery (46.6%); the median hospitalization time was 5.9 days (range 2-27) and the postoperative complication rate was 18%. Open surgery was performed in 70 patients (53.4%); the median length of stay was 9 days (range 4-48) and the postoperative complication rate was 22.9%. The median follow-up time was 70 months. The 5-year overall survival was 34% in the robotic group and 31% in the thoracotomy group. Robotic surgery can be considered safe and feasible not only for early stages but also for the treatment of locally advanced NSCLC.
Keyphrases
- minimally invasive
- locally advanced
- end stage renal disease
- rectal cancer
- small cell lung cancer
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- neoadjuvant chemotherapy
- chronic kidney disease
- peritoneal dialysis
- healthcare
- radiation therapy
- coronary artery bypass
- clinical trial
- patients undergoing
- patient reported outcomes
- pulmonary hypertension
- acute coronary syndrome
- deep learning
- artificial intelligence
- epidermal growth factor receptor
- health information
- patient reported
- weight loss
- electronic health record
- thoracic surgery
- free survival